Gebhard Neyer, Ph.D.

 

Gebhard Neyer, Ph.D., MBA, is currently the Senior Vice President of Product Development at Nuvie Bio.

 

Gebhard has over 30 years of R&D operating experience, from startup to big pharma, with peptides, small molecules, and medical devices in a multitude of indications.

 

Most recently he was Co-Founder, COO and Head of Drug Development of Ocelot Bio, a VC-backed biotech developing a peptide therapeutic in end-stage liver disease.

 

Before his pivot to Ocelot, Gebhard served as the acting head of the Ferring Research Institute in San Diego, Vice President of Project and Portfolio Management at Ferring Pharmaceuticals, and on Ferring’s early-stage drug development governance committee.

 

Earlier in Gebhard’s career, he led drug development efforts at Neurocrine Biosciences and Pfizer in CNS, oncology, and ophthalmology indications. 

 

Prior to joining the life science industry, Gebhard was a post-doctoral fellow with Nobel Laureate George Olah at the University of Southern California, Los Angeles.

 

Gebhard has a Doctorate in Chemistry from Technische Universität München and an MBA from California State University, Long Beach.